Appeal No. 1996-2209
Application No. 08/031,346
producing the germicidally treated suspension includes taking a body fluid, such as urine or
blood from a person suffering from one of the indicated illnesses and desaggregating or
fractionating the body fluids by reducing the body fluids to individual fractions of sub-cell size
substances by cell lysis. The specification suggests that only after breaking up or destruction
of the cell membrane are many very important immune-modulatory substances accessible to
oxidation. Specification, page 13. Cell lysis can be performed mechanically, enzymatically
and/or osmotically. More particularly, cell lysis may occur by means of homogenization,
freezing, osmosis or by the use of proteolytic enzymes such as pepsin, papain or bromelain.
Id.
Ozonation or irradiation of each individual fraction is conducted to provoke a
substantially stronger alteration process of the proteins, lipids and other structures, than
occurs from ozonation of untreated (unfractionated) blood. Specification, page 10. After
separate treatment of the fractions with ozone or irradiation, either part or all of the
fractionated initial substances are then recombined to form a uniform suspension.
Specification, page 14.
Grounds of Rejection
1. Claims 1-26 stand rejected under 35 U.S.C. § 112, first paragraph as unpatentable for
lack of enablement.
2. Claims 1-26 stand rejected under 35 U.S.C. § 101 as unpatentable for lack of utility.
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007